

Non-voting Federal Liaisons, without limit, may be solicited, as needed, as ex officio members.

Equal opportunity practices regarding membership appointments to the Committee will be aligned with HHS policies. To the extent possible, HHS will ensure the Committee membership is balanced in expertise, experience, education, and institutional affiliation.

Members of the Committee will be classified as Special Government Employees (SGE) during their term of appointment and, as such, are subject to the ethical standards of conduct for federal employees. Upon entering the position and annually throughout the term of appointment, members of the Committee will be required to complete and submit a report of their financial holdings.

*Nominations and Appointments for Memberships:* Nominees, including self-nominees, will be considered for appointment as members of the Committee. Only complete nomination packages submitted on time will be considered. To be considered for an appointment, submission of the following information for each nominee is required: (1) a cover letter that clearly states the name and place of work of the nominee, the rationale for the nomination, and a statement that the nominee would be willing to serve as a member of the Committee, if selected; (2) the name, address, telephone number, and email address for the individual being nominated and the nominator, if applicable; and (3) a copy of the nominee's resume or curriculum vitae. Nominees with no professional affiliation may submit an optional letter of recommendation.

The curriculum vitae should include the following information: (a) education; (b) experience (current and former); (c) affiliations; (d) current memberships (expert panels, committees, or other relevant groups, including positions held); (e) any peer-reviewed publications (for past 5 years); (f) any oral presentations (for past 5 years); (g) editorials, opinion pieces, and blogs (for past 5 years); (h) grants, contracts, or research funding (for past 15 years); (i) name of any corporation, professional society, association, panel, company, firm, government agency (Federal, State, and local), research organization, educational institution, committee, or other organization or institution (government, private, and not-for-profit; domestic and foreign) in which the nominee's services have been, will be, or are expected to be provided, with or without compensation, including on a part-time or seasonal basis as an officer, medical staff, board member, owner,

trustee, director, expert advisor, consultant (paid or unpaid), official spokesperson, member of speakers bureau, or expert witness (for past 5 years and upcoming); (j) other paid travel or honoraria received, not included above (for past 5 years). If the nominee does not have anything to report for the sections, indicate "none." Web links to publications, presentations, and other materials available online are requested, when available.

Where prohibited by Federal law or regulations, nominations will not be accepted directly from HHS research and promotion boards. Self-nominations and nominations by members of research and promotion boards in their individual capacity will be considered. Federal employees should not be nominated for consideration for appointment to this Committee.

Dated: November 2, 2023.

**Xavier Becerra,**

*Secretary, Department of Health and Human Services.*

[FR Doc. 2023-24586 Filed 11-16-23; 8:45 am]

**BILLING CODE 4150-03-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, November 27, 2023, 09:00 a.m. to November 29, 2023, 06:00 p.m., Crowne Plaza National Airport, 1480 Crystal Drive, Arlington, VA 22202 which was published in the **Federal Register** on September 25, 2023, 88 FR 67334.

This notice is being amended to change the location to Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852, and change the meeting times to 10:00 a.m. to 6:00 p.m. The meeting dates remains the same. The meeting is closed to the public.

Dated: November 13, 2023.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-25403 Filed 11-16-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Amended Notice of Meeting

Notice is hereby given of an amended meeting notice of the Advisory Committee to the Director, National Institutes of Health, December 14–15, 2023, open meeting that was published in the **Federal Register** on November 13, 2023, 88 FR 77595.

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health.

This will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below. Members of the public are encouraged to attend virtually as space is limited.

Individuals who plan to attend as well as those who need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: <https://videocast.nih.gov/> as space is limited.

*Name of Committee:* Advisory Committee to the Director, National Institutes of Health.

*Date:* December 14, 2023.

*Time:* 9:00 a.m. to 4:45 p.m.

*Agenda:* NIH Director's Report; NIH Public Access Plan; Cancer Moonshot; Addressing the Mental Health Crisis through Research; Assessing the Public Health Threat of Post-Acute Sequelae of SARS CoV-2 Infection (PASC)—NIH RECOVER Initiative; Briefing for the Advisory Committee to the Director (ACD); The Foundation for the National Institutes of Health (FNIH); Other Business of the Committee.

*Date:* December 15, 2023.

*Time:* 9:00 a.m. to 2:45 p.m.

*Agenda:* HeLa Genome Data Access Working Group; Data Access Requests; NIH-Wide Collaborative Initiative on Climate Change and Health; Clinical Trial Stewardship; Accessibility Update; Update from the ACD Working Group on Catalyzing the Development and Use of Novel Alternative Methods to Advance Biomedical Research; Update from the ACD Working Group on Re-envisioning NIH-Supported Postdoctoral Training; Other Business of the Committee.

*Place:* National Institutes of Health, Building 1, Wilson Hall, One Center Drive, Bethesda, MD 20892.

*Contact Person:* Cyndi Burrus-Shaw, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive, Building 1, Room 126, Bethesda, MD 20892, 301-496-2433, [shawcy@od.nih.gov](mailto:shawcy@od.nih.gov)

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about-nih/visitor-information/campus-access-security> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <http://acd.od.nih.gov>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: November 13, 2023.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-25376 Filed 11-16-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, November 17, 2023, 10:00 a.m. to 04:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 which was published in the **Federal Register** on November 3, 2023, 88 FR 77102.

This notice is being amended to change this one-day meeting from November 17, 2023, to November 27, 2023. The meeting time remains the same. The meeting is closed to the public.

Dated: November 13, 2023.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-25404 Filed 11-16-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Establishment of the Board of Scientific Counselors, Division of Translational Toxicology, National Institute of Environmental Health Sciences

Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. 1001-1014), the Director, National Institutes of Health (NIH) announces the establishment of the Board of Scientific Counselors, Division of Translational Toxicology, National Institute of Environmental Health Sciences, as authorized by 42 U.S.C. 282(b)(16), section 402(b)(16) of the Public Health Service Act, as amended.

The Director, NIH, has determined that the Board of Scientific Counselors, Division of Translational Toxicology, National Institute of Environmental Health Sciences is in the public interest in connection with the performance of duties imposed on NIH by law, and that these duties can best be performed through the advice and counsel of the committee.

The committee will review and evaluate the intramural program and the work of tenured, tenure track, and staff scientists and physicians and shall also, as requested by the Director, NIH, undertake peer review of extramural funding applications as required by section 492 of the Public Health Service Act, as amended.

Inquiries may be directed to Claire Harris, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or [Claire.Harris@nih.gov](mailto:Claire.Harris@nih.gov).

Dated: November 13, 2023.

**Monica M. Bertagnolli,**

*Director, National Institutes of Health.*

[FR Doc. 2023-25472 Filed 11-16-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Advancing Translational Sciences; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Collaborative and Innovative Acceleration Awards.

*Date:* February 7, 2024.

*Time:* 11:30 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* M. Lourdes Ponce, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1068, Bethesda, MD 20892, (301) 435-0810, [lourdes.ponce@nih.gov](mailto:lourdes.ponce@nih.gov).

*Name of Committee:* National Center for Advancing Translational Sciences Special Emphasis Panel; Understudied Proteins Associated with Rare Diseases (R03) Review.

*Date:* February 29, 2024.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ming Yan, MD, Ph.D. Scientific Review Officer Scientific Review Branch Division of Extramural Activities National Center for Advancing Translational Sciences 6701 Democracy Boulevard, MSC 4874 Bethesda, MD 20892 (301) 827-4312 [ming.yan@nih.gov](mailto:ming.yan@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)